Skip to main content
. Author manuscript; available in PMC: 2016 Jun 1.
Published in final edited form as: Curr Opin Neurol. 2015 Jun;28(3):237–243. doi: 10.1097/WCO.0000000000000195

Table 1.

Ongoing treatment trials in PMS, phase III and selected phase II studies

Agent Disease Course Duration Trial Size Phase
Amiloride (MS-SMART) SPMS 24 months 440 (divided among 4 arms) II
Ibudilast (SPRINT MS) PP, SPMS 24 months 250 II
Ibudilast (MS-SMART) SPMS 24 months 440 (divided among 4 arms) II
Idebonone SPMS 24 months 80 II
Imilecleucel-T SPMS 24 months 180 II
Masitinib PP, SPMS 24 months 450 III
Natalizumab SPMS 24 months 856 III
Ocrelizumab PPMS 24 months 733 III
Riluzole (MS-SMART) SPMS 25 months 440 (divided among 4 arms) II
Spinonimod SPMS 40 months 1530 III
T Cell Receptor Peptide SPMS 12 months 200 II

Source: Authors, data obtained from clinicaltrials.gov